EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity

By J. Bieschke, Jenny Russ, R. Friedrich, Dagmar E. Ehrnhoefer, Heike J Wobst, K. Neugebauer, Erich E. Wanker. Proceedings of the National Academy of Sciences of the United States of America, 2010

970 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/b1b40653c2a98166aa1e4e2008365970fbd42e6d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Michael Lawson
2. Vladimir N Uversky
3. Leonidas Stefanis
4. M. Valko
5. D. Vondrakova
6. K. Jomová

In Physiology

1. Michael Lawson
2. Jessica W. Wu
3. Vladimir N Uversky
4. Leonidas Stefanis
5. M. Valko
6. L. Breydo
7. D. Vondrakova
8. K. Jomová

Citations in the corpus

• α-Synuclein in Parkinson's disease. (2012, background): “An example of such natural products could be the green tea derivative EGCG (Bieschke et al. 2010) or the natural product scyllo inositol (Vekrellis et al.”
• Metals, oxidative stress and neurodegenerative disorders (2010, positive): “These findings suggest that EGCG is a potent remodeling agent of mature amyloid fibrils [80].”
• Α-synuclein misfolding and Parkinson's disease. (2012, methodology): “synuclein or its fibrils were incubated with EGCG [387], curcumin [388–390], other polyphenols [391], an anti-PD drug selengiline [392]”